Indication (pathologie):
Primary progressive multiple sclerosis
Identifiant SNOMED-CT:
SCTID 428700003
Etudes cliniques
-
A multicentre, non-interventional study to assess the real-world effectiveness of ocrelizumab in patients with relapsing or primary progressive multiple sclerosis - the musicale studyIndication (pathologie):Progressive relapsing multiple sclerosisIdentifiant SNOMED-CT:SCTID 724778008Phase de l'étude: Phase IVRecrutement: Ouvert
-
An open-label, multicenter, extention study to evaluate the safety and efficacy of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyIndication (pathologie):EpilepsyIdentifiant SNOMED-CT:SCTID 84757009Phase de l'étude: Phase IIRecrutement: Ouvert
-
Multi-modal and bedside electrophysiological prognostic biomarkers for recovery in ischemic strokeIndication (pathologie):Ischemic strokeIdentifiant SNOMED-CT:SCTID 422504002Recrutement: Ouvert
-
A prospective, open-label, multicenter, single-arm observational registry to describe adherence in relapsing remitting multiple sclerosis patients being prescribed teriflunomide (AUBAGIO®) in Belgium and Luxembourg in routine clinical practiceIndication (pathologie):Multiple sclerosisIdentifiant SNOMED-CT:SCTID 24700007Recrutement: Ouvert
-
Protocol I8D-MC-AZFD: A randomized, double-blind, delayed-start study of LY3314814 (AZD3293) in early alzheimer’s disease dementia (extension of study AZES, the AMARANTH study)Indication (pathologie):Alzheimer's diseaseIdentifiant SNOMED-CT:SCTID 26929004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A 2-year prospective study to assess health-related quality of life in subjects with highly-active relapsing multiple sclerosis treated with MAVENCLAD®Indication (pathologie):Progressive relapsing multiple sclerosisIdentifiant SNOMED-CT:SCTID 724778008Phase de l'étude: Phase IVRecrutement: Ouvert
-
A prospective, multicenter, observational post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosisIndication (pathologie):Multiple sclerosisIdentifiant SNOMED-CT:SCTID 24700007Recrutement: Ouvert
-
A randomized, double-blind, placebo-controlled, dose finding study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyIndication (pathologie):EpilepsyIdentifiant SNOMED-CT:SCTID 84757009Phase de l'étude: Phase IIRecrutement: Ouvert
-
A multi-centre proof-of-performance clinical study to validate blood-based biomarker candidates for the diagnosis of Alzheimer’s diseaseIndication (pathologie):Alzheimer's diseaseIdentifiant SNOMED-CT:SCTID 26929004Recrutement: Ouvert
-
Proteomic profiling for novel biomarkers of risk of conversion to multiple sclerosis and of disease severityIndication (pathologie):Multiple sclerosisIdentifiant SNOMED-CT:SCTID 24700007Recrutement: Ouvert
-
A multicenter, double-Blind, randomized, placebo-controlled trial with an open-label extension phase of perampanel as adjunctive treatment in subjects at least 2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndromeIndication (pathologie):EpilepsieIdentifiant SNOMED-CT:SCTID: 84757009Indication (pathologie):Lennox-Gastaut SyndromeIdentifiant SNOMED-CT:SCTID: 230418006Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A randomized, double-blind, placebo-controlled, dose finding study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyIndication (pathologie):EpilepsieIdentifiant SNOMED-CT:SCTID: 84757009Phase de l'étude: Phase IIRecrutement: Ouvert